Reproducibility Failures That Disqualify CFPS Systems From Automated Variant Screening

For cell-free protein synthesis for high-throughput variant screening, the decisive requirement is comparable activity scores across wells, batches, and time points (not simply expression on a liquid-handling robot). A suitable CFPS system needs controlled extract manufacturing, documented formulations, lot-level QC data, and compatibility with plate-based automation. Reproducibility failures disqualify systems when they cascade from extract variability through reagent drift and folding differences into activity scores that no longer rank variants reliably.

Why automated variant screening breaks when CFPS reproducibility fails

ML-assisted protein design depends on screening tens to hundreds of designed proteins and using the results to guide subsequent design. The model needs ranked, monotonic activity scores across that library. Comparability is the essential requirement for those scores. If the same variants receive different ranks on different days or in different wells because the reaction environment changes, the resulting fitness landscape describes the screening system as well as the proteins.

CFPS is attractive because it decouples protein synthesis from cell viability, removes genomic background, and can express proteins toxic to host cells. Those advantages support screening without transforming and culturing cells for each construct. Automation makes this route appealing for parallel expression, but dispensing reactions the same way each time does not ensure that they behave the same way. Establishing whether each reaction provides an equivalent basis for measuring variant function requires tracing a cascade of failures from the extract to the final assay, rather than treating reproducibility as a single quality metric.

How batch-to-batch extract variability corrupts the activity baseline

Cell-derived extracts contain dozens of enzymes and cofactors whose concentrations and activities jointly determine CFPS performance. Small changes in how source cells are cultured, when they are harvested, or which lysis method is used can change translation rates and the capacity for energy regeneration. Because the components act together, an extract that performs differently does not necessarily reveal which component caused the change. A preparation protocol can therefore be followed consistently without producing an identical biochemical environment in every batch.

For screening, the first consequence is an unstable baseline. If two extract batches give different expression levels from the same control construct, the activity scores from those batches cannot be compared directly. A variant can appear more active because its reaction produced more protein, rather than because the protein has better functional properties. The reaction environment then becomes a confound in the ranking. This is especially damaging when a library spans batches, because the differences between batches become entangled with the differences between sequences.

Melinek et al. (2023), working through the CPI/UCL/Merck KGaA/eXmoor Pharma Concepts collaboration, spent 36 months developing an industrial-scale extract manufacturing process. The collaboration concluded that demonstrating consistent extract quality was challenging without a full understanding of Raw Material Attributes and their interactions with reaction conditions and product. Its practical response was to screen and adjust reaction parameters after extract preparation to manage the remaining variability. The variability remaining after manufacturing control gives users little reason to expect in-house preparation to remove it upstream, so they need access to the parameters they can adjust downstream.

Lysate instability and component activity drift during a screening run

Batch variability concerns the environment a reaction starts with, while within-run drift concerns how that environment changes during storage and use. A batch that passes its first quality checks can still lose activity as screening goes on. Reactions run early and late may use material from the same lot yet have different levels of biochemical activity. This temporal difference adds to the batch effect.

The mechanism lies in the coupled nature of transcription and translation. CFPS depends on energy regeneration systems and enzymatic activities that are sensitive to temperature fluctuations, freeze-thaw cycles, and extended storage. Degradation of a single component can propagate through the reaction and change its output. Lysate instability and fluctuations in component activity consequently require calibration and standardization across experiments. A nominally unchanged formulation does not establish that its components remain equally active throughout use.

Cold-chain dependence makes this a practical constraint for automation. Reagents may sit on a liquid-handling deck for hours, while current systems need cold-chain storage and have a limited shelf-life. Lyophilization has been proposed as a stabilization strategy, but activity loss upon reconstitution can trade storage stability for reduced yield and consistency. The tradeoff reaches directly into assay interpretation. In a 96- or 384-well screening campaign, time-dependent drift can resemble a difference in variant activity unless sufficient controls separate the two, adding experimental work that erodes the throughput advantage.

How undocumented formulations remove the ability to diagnose or correct failures

An undocumented formulation turns a biological problem into a diagnostic dead end. When activity falls, the user lacks the component-level reference needed to identify a formulation difference, a protocol problem, or a target-specific requirement as the cause. The missing information limits corrective action at its source. The methods used for extract preparation already differ widely between laboratories, so a protocol without a published formulation gives them no shared way to check whether a preparation matches the intended system.

The collaboration identified limited technology transfer and knowledge sharing as barriers to CFPS development. Formulation opacity therefore extends beyond an individual supplier’s disclosure choices. It also weakens the field’s ability to transfer working reaction conditions and interpret failures across laboratories. In an ML workflow, that diagnostic gap makes it harder to identify which activity scores reflect compromised reactions and should be excluded from training. An assay can report a number without revealing that the conditions producing it were unsuitable.

Published formulations and lot-level QC data address different parts of this gap. The formulation records which components should be present, while QC data records how a given lot performed under the conditions on record. Neither eliminates biological variability on its own. Together, however, they provide a basis for attributing deviations and evaluating reagent substitutions against a known specification. Without that reference, supply-chain substitutions introduce another uncertainty into a workflow already sensitive to component activity.

Why multi-domain and folding-sensitive proteins amplify every upstream failure

For folding-sensitive targets, protein quantity is only part of the problem. Functional protein production depends on multi-domain assembly, correct disulfide bond formation, and chaperone-assisted folding. A change in extract composition can therefore alter measured activity through the folding environment even when the reaction still produces protein. These targets expose a layer of variability that an expression-only control may not capture.

Toxic or insoluble proteins sharpen this distinction because they are among the targets for which CFPS offers a clear advantage over cell-based expression. Chaperone-enriched extracts can significantly enhance protein solubility, but chaperone concentration itself differs across extract batches. A system selected to escape a host-cell limitation can consequently introduce an extract-dependent folding limitation, and an undocumented formulation prevents the user from identifying the relevant difference.

Post-translational modifications add further dependencies. Prokaryotic CFPS cannot perform N-linked glycosylation without extensive engineering, while most eukaryotic systems require supplementation for complex modifications. Each supplement adds a component that must be kept consistent from lot to lot. LenioBio’s ALiCE white paper describes a system derived from Nicotiana tabacum BY-2 cells that was developed to address limitations including low batch-mode yields, low scalability, and inadequate implementation of PTMs. The yield limitation can otherwise require expensive continuous-exchange formats, illustrating why extract origin and operating format cannot be separated from target requirements.

Differences between batches change the folding environment at the start, and component drift can change it further during use. Small biochemical differences can cause large shifts in how well the protein works. If the formulation is also undocumented, the user cannot readily attribute those shifts to the supporting reaction components. A platform that expresses a straightforward reference protein consistently has therefore not necessarily established reproducibility for a multi-domain or PTM-requiring library.

Where the cascade is most disqualifying: the assay readout layer

The final activity assay integrates protein production, folding, and function into one signal. By that stage, extract variation and reagent drift can already have altered both the amount of protein and the fraction that is functional. The readout alone does not show how much each of those factors contributes. A high score may identify a genuinely improved variant, or a reaction that happened to provide more favorable expression conditions. Once those scores become ML training data, uncertainty in the reaction environment becomes uncertainty in the relationship between sequence and fitness.

Thornton et al.’s CFPS-ML protease screening study, published in ACS Synthetic Biology in May 2025, provides strong evidence that CFPS can support this workflow under controlled conditions. Its fluorescence-based activity assays correlated well with activity measured from purified proteins. Of the 80 total variants screened, the study found several protease variants with better kinetic properties, providing substantive validation of the workflow. It shows that a cell-free assay can generate useful functional measurements for ML-assisted screening.

However, the study restricted variants to a maximum of three simultaneous amino acid differences and screened the two mutagenesis regions separately. The work tested a low-diversity, single-target screen with a simple fluorescence readout, rather than a library spanning broad sequence contexts. Constrained diversity reduces the opportunity for sequence-dependent differences in expression and folding to dominate the activity signal. It does not establish that those differences remain controlled as library diversity expands.

In broader libraries, it becomes harder to tell differences in expression from differences in activity. A noisy CFPS system cannot resolve that confound without purification, which defeats the throughput advantage of direct screening. The protease study therefore answers one question without settling another. It demonstrates that carefully controlled CFPS can support ML screening, but it does not show that any robot-compatible system will produce reliable training data for diverse targets. The distinction is between a validated assay under defined conditions and a platform whose reproducibility remains dependable across a wider screening program.

Which CFPS systems can anchor an automated variant screening workflow?

Researchers selecting a platform need to evaluate the controls that interrupt the cascade. Extract consistency must be managed during manufacturing, with a stated method for handling the variability that remains. The collaboration’s downstream parameter adjustment provides a minimum operational benchmark.

Formulation transparency supplies the next criterion because a screening program must be able to investigate failures and accommodate changes. Published formulations let users check substitute lots against the intended chemistry and find the components that matter for a new target class. Lot-level QC adds the operational baseline. A reference protein expressed at a documented yield under documented conditions gives the user a concrete point of comparison for designing controls and detecting drift. A reproducibility claim can be assessed when it states the conditions used and the basis for deciding whether the results pass.

Automation compatibility must also be treated as a design requirement. Compatibility with standard plates and liquid-handling workflows is necessary for screening hundreds of variants in parallel, but physical dispensability is not enough. Reagent stability during the intended workflow remains essential. A system designed for plate-based automation can reduce operator-introduced variability, while its documented operating conditions and QC data provide the basis for judging whether biological activity remains consistent. That same evaluation must also cover the folding and modification requirements of each target.

No single yield claim resolves all these questions. A system suitable for a constrained protease library may not be suitable for a diverse set of folding-sensitive proteins, even when both screens use the same plate format. The evidence must match the target class, how batches will be used, and how long the system will be in use. Before committing a variant library, ask whether the supplier publishes its formulation, releases lot-level QC data, and has characterized extract consistency across batches, and treat any missing answer as a barrier to qualification.